<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00812838</url>
  </required_header>
  <id_info>
    <org_study_id>11-07-40-04</org_study_id>
    <nct_id>NCT00812838</nct_id>
  </id_info>
  <brief_title>H-22411: BOTOX® for Peyronie's Disease</brief_title>
  <official_title>The Efficacy of Botulinum Toxin Type a in Treating Peyronie's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mohit Khera</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peyronie's disease is a condition in which a plaque, or hard lump, forms on the penis. It
      causes hardened tissue, pain, and an abnormal bending in the penis. These symptoms are more
      severe during an erection. Significant bending of the penis can result in pain, poor
      erections, and an inability to engage in sexual intercourse.

      This disease affects about 3% of the male population. The average age of onset of this
      disease is 57 years old. The cause of the disease is unknown. However, many believe that it
      may be due to trauma to the penis (such as injury or extremely vigorous sexual activity).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatments for this disease have been limited and often unsuccessful. The goal of treatment
      is to reduce pain and maintain sexual function. Oral medicines that prevent plaque formation
      and promote plaque breakdown have not been effective. Many patients with the disease will
      require injections of medicines directly into the plaque. These injections have been used for
      over 50 years in the treatment of major Peyronie's disease. The disease often resolves on its
      own without treatment. Surgery may be performed to remove hardened tissue in the penis.
      However, surgery is not done during the first 12 months of the disease.

      There are 2 phases of the disease: the active phase and the inactive phase. The active phase
      usually occurs during the first 12 months of the disease. The stabilization of the plaque is
      known as the inactive phase. We are inviting men with stable disease to take part in this
      study which will test BOTOX® versus a placebo (a placebo contains no medicine).

      This will be a randomized, placebo-controlled, cross-over, single-center trial. The placebo
      group has the option to cross over to the treatment arm (ARM 1) of the study at the end of
      their 16 weeks of placebo arm (ARM 2). Study drug is Botulinum toxin type A (BOTOX®).
      Subjects who meet the inclusion criteria for the study will be randomized to either the
      treatment or placebo arm.

        -  Treatment: Injection solution will consist of 100 units of BOTOX® in 10 cc of
           preservative free normal saline, or

        -  Placebo: Injection solution will consist of 10 cc preservative free normal saline.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 7, 2009</start_date>
  <completion_date type="Actual">January 15, 2019</completion_date>
  <primary_completion_date type="Actual">February 15, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Percent Change of Penile Curvature in Degrees</measure>
    <time_frame>Baseline (Pre-Treatment Screening Visit) to end of treatment at week 16</time_frame>
    <description>Measured by a protractor from pictures taken at baseline (pre-treatment screening visit) and end of treatment at week 16
*Crossover subjects were added to Experimental Group for analysis*
Negative value equates to a reduction in curvature Positive value equates to an increase in curvature</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Penile Blood Flow for Peak Systolic Velocity (PSV) and End-diastolic Velocity (EDV)</measure>
    <time_frame>Baseline (Pre-Treatment Screening Visit) to end of treatment at week 16</time_frame>
    <description>Results of penile doppler ultrasound from baseline/screening visit to end of treatment at week 16 will be compared.
peak systolic velocity (PSV) and end-diastolic velocity (EDV) are assessed here.
Change is calculated as week 16 values - screening visit values
Negative values are a decrease in velocity Positive values are an increase in velocity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Penile Blood Flow for Diameter</measure>
    <time_frame>Baseline (Pre-Treatment Screening Visit) to end of treatment at week 16</time_frame>
    <description>Results of penile doppler ultrasound from the baseline/screening visit to end of treatment at week 16 will be compared.
Diameter is assessed here.
Change is calculated as week 16 values - screening visit values
Negative values are a decrease in diameter Positive values are an increase in diameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Penile Plaque Size</measure>
    <time_frame>Baseline (Pre-Treatment Screening Visit) to end of treatment at week 16</time_frame>
    <description>Results of ultrasound at baseline/screening visit to end of treatment at week 16 will be compared.
*Crossover subjects were added to Experimental Group for analysis*
Change is calculated as week 16 values values minus screening visit values
Increase in value equates to increased plaque size Decrease in value equates to decreased plaque size</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in International Index of Erectile Function Scores (IIEF)</measure>
    <time_frame>Baseline (Pre-Treatment Screening Visit) to end of treatment at week 16</time_frame>
    <description>Subject's average scores on IIEF at baseline/screening visit to end of treatment at week 16 are compared
The subscale measures self-reported erectile function. Maximum score is 30, Minimum is 0. A score of 0 is the absolute best outcome. A score of 30 is the absolute worst outcome. Erectile Function score is a summation of questions 1,2,3,4, and 15. This study is assessing their erectile function and not the other subscales.
The other subscale scores are :
Orgasmic Function (Questions 9, 10); Maximum score = 10, Minimum score = 0
Sexual Desire (Questions 11, 12); Maximum score = 10, Minimum score = 0
Intercourse Satisfaction (Questions 6, 7, 8); Maximum score = 15, Minimum score = 0
Overall Satisfaction (Question 13, 14): Maximum score = 10, Minimum score = 0
Subscales are not combined to make a total composite score.
*Crossover subjects were added to Experimental Group for analysis*</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Peyronie's Disease</condition>
  <arm_group>
    <arm_group_label>100 units of Botulinum Toxin Type A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection solution will consist of 10 cc preservative free normal saline
Subjects had the choice of crossing over to ARM 1 at the end of 16 weeks.
Cross-over: For subjects in Arm 2, crossover to BOTOX treatment will begin after the Week 16 Visit by repeating the study schedule as for Week 0 to Week 16.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 units of Botulinum Toxin Type A</intervention_name>
    <description>Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque</description>
    <arm_group_label>100 units of Botulinum Toxin Type A</arm_group_label>
    <other_name>BOTOX®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Preservative free normal saline</intervention_name>
    <description>Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque</description>
    <arm_group_label>Normal saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>100 units Botulinum Toxin A</intervention_name>
    <description>Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque</description>
    <arm_group_label>Normal saline</arm_group_label>
    <other_name>Cross-over</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with stable Peyronie's plaques.

          -  Males at least 18 years of age

          -  Must give informed consent.

        Exclusion Criteria:

          -  Subjects in the active phase of Peyronie's disease.

          -  Subjects with less than 1 year history of Peyronie's disease.

          -  Subjects taking oral medications for Peyronie's disease which include Trental, Viagra,
             vitamin E, colchicines, L-arginine, and tamoxifen. There will be a 2 week wash-out
             period if patients are on these medications.

          -  Subjects with more than 1 penile plaque will be excluded from the study.

          -  Subjects with calcified plaques demonstrated by ultrasound will be excluded from the
             study.

          -  Known allergy or sensitivity to any components of the study medication (botulinum
             toxin A), anesthetics, or any other product associated with the treatment and general
             study procedures.

          -  Any medical condition or neuromuscular disorder that may put the patient at increased
             risk with exposure to botulinum toxin A (BTX-A), including myasthenia gravis,
             Eaton-Lambert syndrome, or amyotrophic lateral sclerosis.

          -  Patient taking aminoglycosides or any drug known to interfere with neuromuscular
             transmission.

          -  Patient has hemophilia or other clotting factor deficiencies or disorders that cause
             bleeding diathesis.

          -  Patient must not be taking aspirin, non-steroidal anti-inflammatory drugs, or Coumadin
             for 7 or more days prior to Botox injection.

          -  Episode of unstable angina pectoris, myocardial infarction, transient ischemic attack,
             or cerebrovascular accident within the past 6 months.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohit Khera, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Khera M, Boone TB, Smith CP. Botulinum toxin type A: a novel approach to the treatment of recurrent urethral strictures. J Urol. 2004 Aug;172(2):574-5.</citation>
    <PMID>15247734</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2008</study_first_posted>
  <results_first_submitted>January 13, 2020</results_first_submitted>
  <results_first_submitted_qc>February 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 17, 2020</results_first_posted>
  <last_update_submitted>February 3, 2020</last_update_submitted>
  <last_update_submitted_qc>February 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Mohit Khera</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Penile Induration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Data will be published in aggregate.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 30, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT00812838/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental</title>
          <description>100 units of Botulinum Toxin Type A Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline</description>
        </group>
        <group group_id="P2">
          <title>Placebo Comparator</title>
          <description>Normal saline Injection solution will consist of 10 cc preservative free normal saline.
Optional Cross-over: For subjects in Arm 2, crossover to BOTOX treatment will begin after the Week 16 Visit by repeating the study schedule as for Week 0 to Week 16.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period of 16 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Optional Crossover of 16 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Per the study protocol, two arms of the study are analyzed; the experimental arm and the placebo arm
*4 subjects cross over from ARM 2 to ARM 1after 16 weeks. Crossover subjects were added to Experimental Group for analysis with Adverse Events, International Index of Erectile Function, Penile Curvature, and Reduction in Plaque Size*</population>
      <group_list>
        <group group_id="B1">
          <title>Experimental</title>
          <description>100 units of Botulinum Toxin Type A Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline
*Crossover subjects were added to Experimental Group for analysis*</description>
        </group>
        <group group_id="B2">
          <title>Placebo Comparator</title>
          <description>Normal saline Injection solution will consist of 10 cc preservative free normal saline.
Optional Cross-over: For subjects in Arm 2, crossover to BOTOX treatment will begin after the Week 16 Visit by repeating the study schedule as for Week 0 to Week 16.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Per the study protocol, two arms of the study are analyzed; the experimental arm and the placebo arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>Per the study protocol, two arms of the study are analyzed; the experimental arm and the placebo arm</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.86" spread="4.741"/>
                    <measurement group_id="B2" value="57.83" spread="3.710"/>
                    <measurement group_id="B3" value="58.38" spread="4.154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Per the study protocol, two arms of the study are analyzed; the experimental arm and the placebo arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Per the study protocol, two arms of the study are analyzed; the experimental arm and the placebo arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Per the study protocol, two arms of the study are analyzed; the experimental arm and the placebo arm</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Percent Change of Penile Curvature in Degrees</title>
        <description>Measured by a protractor from pictures taken at baseline (pre-treatment screening visit) and end of treatment at week 16
*Crossover subjects were added to Experimental Group for analysis*
Negative value equates to a reduction in curvature Positive value equates to an increase in curvature</description>
        <time_frame>Baseline (Pre-Treatment Screening Visit) to end of treatment at week 16</time_frame>
        <population>*Crossover subjects were added to Experimental Group for analysis*</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>100 units of Botulinum Toxin Type A Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Normal saline Injection solution will consist of 10 cc preservative free normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Average Percent Change of Penile Curvature in Degrees</title>
          <description>Measured by a protractor from pictures taken at baseline (pre-treatment screening visit) and end of treatment at week 16
*Crossover subjects were added to Experimental Group for analysis*
Negative value equates to a reduction in curvature Positive value equates to an increase in curvature</description>
          <population>*Crossover subjects were added to Experimental Group for analysis*</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.73" spread="57.69"/>
                    <measurement group_id="O2" value="2.429" spread="81.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5154</p_value>
            <p_value_desc>This will be a pilot study; it was assessed that 10 subjects in each arm, for a total of 20 subjects, will allow us to determine if the therapy is effective. To allow for screen failures, 45 subjects are planned for screening.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Penile Blood Flow for Peak Systolic Velocity (PSV) and End-diastolic Velocity (EDV)</title>
        <description>Results of penile doppler ultrasound from baseline/screening visit to end of treatment at week 16 will be compared.
peak systolic velocity (PSV) and end-diastolic velocity (EDV) are assessed here.
Change is calculated as week 16 values - screening visit values
Negative values are a decrease in velocity Positive values are an increase in velocity</description>
        <time_frame>Baseline (Pre-Treatment Screening Visit) to end of treatment at week 16</time_frame>
        <population>*Penile Doppler ultrasound was not performed on optional crossover patients. Data reflects scores derived from Experimental and Placebo group analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>100 Units of Botulinum Toxin Type A</title>
            <description>Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline
100 units of Botulinum Toxin Type A: Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Injection solution will consist of 10 cc preservative free normal saline
Preservative free normal saline: Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Penile Blood Flow for Peak Systolic Velocity (PSV) and End-diastolic Velocity (EDV)</title>
          <description>Results of penile doppler ultrasound from baseline/screening visit to end of treatment at week 16 will be compared.
peak systolic velocity (PSV) and end-diastolic velocity (EDV) are assessed here.
Change is calculated as week 16 values - screening visit values
Negative values are a decrease in velocity Positive values are an increase in velocity</description>
          <population>*Penile Doppler ultrasound was not performed on optional crossover patients. Data reflects scores derived from Experimental and Placebo group analysis.</population>
          <units>cm/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre injection Right PSV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65670" spread="5.505"/>
                    <measurement group_id="O2" value="-9.0170" spread="11.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre injection Right EDV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.10200" spread="6.798"/>
                    <measurement group_id="O2" value="-0.8667" spread="3.771"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre injection Left PSV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.263" spread="9.032"/>
                    <measurement group_id="O2" value="-6.4330" spread="12.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre injection Left EDV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.27" spread="8.261"/>
                    <measurement group_id="O2" value="-6.75" spread="11.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes right PSV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.185" spread="28.48"/>
                    <measurement group_id="O2" value="2.1330" spread="6.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes right EDV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.05" spread="19.56"/>
                    <measurement group_id="O2" value="-0.1417" spread="3.944"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes left psv</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.863" spread="17.68"/>
                    <measurement group_id="O2" value="-6.6830" spread="22.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minutes left edv</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="10.80"/>
                    <measurement group_id="O2" value="3.5" spread="10.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes right PSV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.917" spread="20.91"/>
                    <measurement group_id="O2" value="-15.52" spread="34.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes right EDV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.22" spread="22.82"/>
                    <measurement group_id="O2" value="1.55" spread="5.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes left PSV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.183" spread="10.81"/>
                    <measurement group_id="O2" value="-15.10" spread="40.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minutes left EDV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.267" spread="11.58"/>
                    <measurement group_id="O2" value="3.367" spread="6.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This will be a pilot study; it was assessed that 10 subjects in each arm, for a total of 20 subjects, will allow us to determine if the therapy is effective. To allow for screen failures, 45 subjects are planned for screening.
This analysis pertains to both categories</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3009</p_value>
            <p_value_desc>This applies to 100 units of Botulinum Toxin Type A arm vs the Normal saline arm</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Penile Blood Flow for Diameter</title>
        <description>Results of penile doppler ultrasound from the baseline/screening visit to end of treatment at week 16 will be compared.
Diameter is assessed here.
Change is calculated as week 16 values - screening visit values
Negative values are a decrease in diameter Positive values are an increase in diameter</description>
        <time_frame>Baseline (Pre-Treatment Screening Visit) to end of treatment at week 16</time_frame>
        <population>*Penile Doppler ultrasound was not performed on optional crossover patients. Data reflects scores derived from Experimental and Placebo group analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>100 units of Botulinum Toxin Type A Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Normal saline Injection solution will consist of 10 cc preservative free normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Penile Blood Flow for Diameter</title>
          <description>Results of penile doppler ultrasound from the baseline/screening visit to end of treatment at week 16 will be compared.
Diameter is assessed here.
Change is calculated as week 16 values - screening visit values
Negative values are a decrease in diameter Positive values are an increase in diameter</description>
          <population>*Penile Doppler ultrasound was not performed on optional crossover patients. Data reflects scores derived from Experimental and Placebo group analysis.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre injection right Diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" spread="0.8539"/>
                    <measurement group_id="O2" value="0.1700" spread="0.7208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pre injection left diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04167" spread="0.5869"/>
                    <measurement group_id="O2" value="0.3983" spread="0.4565"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minute right diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34200" spread="4.006"/>
                    <measurement group_id="O2" value="0.2917" spread="0.6719"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 minute left diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75330" spread="2.551"/>
                    <measurement group_id="O2" value="0.0750" spread="0.9000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minute right diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.43700" spread="3.952"/>
                    <measurement group_id="O2" value="-0.3550" spread="0.6469"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>15 minute left diameter</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43500" spread="2.571"/>
                    <measurement group_id="O2" value="-0.1867" spread="1.203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This will be a pilot study; it was assessed that 10 subjects in each arm, for a total of 20 subjects, will allow us to determine if the therapy is effective. To allow for screen failures, 45 subjects are planned for screening.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0166</p_value>
            <p_value_desc>This applies to 100 units of Botulinum Toxin Type A arm vs the Normal saline arm</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Penile Plaque Size</title>
        <description>Results of ultrasound at baseline/screening visit to end of treatment at week 16 will be compared.
*Crossover subjects were added to Experimental Group for analysis*
Change is calculated as week 16 values values minus screening visit values
Increase in value equates to increased plaque size Decrease in value equates to decreased plaque size</description>
        <time_frame>Baseline (Pre-Treatment Screening Visit) to end of treatment at week 16</time_frame>
        <population>*Crossover subjects were added to Experimental Group for analysis*</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>100 units of Botulinum Toxin Type A Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Normal saline Injection solution will consist of 10 cc preservative free normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Penile Plaque Size</title>
          <description>Results of ultrasound at baseline/screening visit to end of treatment at week 16 will be compared.
*Crossover subjects were added to Experimental Group for analysis*
Change is calculated as week 16 values values minus screening visit values
Increase in value equates to increased plaque size Decrease in value equates to decreased plaque size</description>
          <population>*Crossover subjects were added to Experimental Group for analysis*</population>
          <units>cubic millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>screening visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="717.5" spread="827.4"/>
                    <measurement group_id="O2" value="485.8" spread="599.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198.9" spread="220.8"/>
                    <measurement group_id="O2" value="319.0" spread="252.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This will be a pilot study; it was assessed that 10 subjects in each arm, for a total of 20 subjects, will allow us to determine if the therapy is effective. To allow for screen failures, 45 subjects are planned for screening.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.8566</p_value>
            <p_value_desc>Threshold for statistical significance was &lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in International Index of Erectile Function Scores (IIEF)</title>
        <description>Subject's average scores on IIEF at baseline/screening visit to end of treatment at week 16 are compared
The subscale measures self-reported erectile function. Maximum score is 30, Minimum is 0. A score of 0 is the absolute best outcome. A score of 30 is the absolute worst outcome. Erectile Function score is a summation of questions 1,2,3,4, and 15. This study is assessing their erectile function and not the other subscales.
The other subscale scores are :
Orgasmic Function (Questions 9, 10); Maximum score = 10, Minimum score = 0
Sexual Desire (Questions 11, 12); Maximum score = 10, Minimum score = 0
Intercourse Satisfaction (Questions 6, 7, 8); Maximum score = 15, Minimum score = 0
Overall Satisfaction (Question 13, 14): Maximum score = 10, Minimum score = 0
Subscales are not combined to make a total composite score.
*Crossover subjects were added to Experimental Group for analysis*</description>
        <time_frame>Baseline (Pre-Treatment Screening Visit) to end of treatment at week 16</time_frame>
        <population>*Crossover subjects were added to Experimental Group for analysis*</population>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>100 units of Botulinum Toxin Type A Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>Normal saline Injection solution will consist of 10 cc preservative free normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in International Index of Erectile Function Scores (IIEF)</title>
          <description>Subject's average scores on IIEF at baseline/screening visit to end of treatment at week 16 are compared
The subscale measures self-reported erectile function. Maximum score is 30, Minimum is 0. A score of 0 is the absolute best outcome. A score of 30 is the absolute worst outcome. Erectile Function score is a summation of questions 1,2,3,4, and 15. This study is assessing their erectile function and not the other subscales.
The other subscale scores are :
Orgasmic Function (Questions 9, 10); Maximum score = 10, Minimum score = 0
Sexual Desire (Questions 11, 12); Maximum score = 10, Minimum score = 0
Intercourse Satisfaction (Questions 6, 7, 8); Maximum score = 15, Minimum score = 0
Overall Satisfaction (Question 13, 14): Maximum score = 10, Minimum score = 0
Subscales are not combined to make a total composite score.
*Crossover subjects were added to Experimental Group for analysis*</description>
          <population>*Crossover subjects were added to Experimental Group for analysis*</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Screening Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.60" spread="11.75"/>
                    <measurement group_id="O2" value="21" spread="12.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.20" spread="11.61"/>
                    <measurement group_id="O2" value="21.50" spread="11.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This will be a pilot study; it was assessed that 10 subjects in each arm, for a total of 20 subjects, will allow us to determine if the therapy is effective. To allow for screen failures, 45 subjects are planned for screening.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0286</p_value>
            <p_value_desc>Threshold for statistical significance is &lt;0.05</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years, 8 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>100 Units of Botulinum Toxin Type A</title>
          <description>Injection solution will consist of 100 units of BOTOX® in 10 cc of preservative free normal saline
100 units of Botulinum Toxin Type A: Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline</title>
          <description>Injection solution will consist of 10 cc preservative free normal saline
Preservative free normal saline: Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>small bowel obstruction</sub_title>
                <description>1, small bowel obstruction; pain pressure in his abdomen</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Cold</sub_title>
                <description>Cold - no treatment provided</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <description>No treatment was provided</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Foot pain</sub_title>
                <description>No treatment was provided</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>increased frequent urination</sub_title>
                <description>increased frequent urination</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>seasonal allergies</sub_title>
                <description>seasonal allergies</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <description>No treatment was provided</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mohit Khera, MD</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713-798-6593</phone>
      <email>mkhera@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

